Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF <sup<V600</sup< Mutation-Positive Melanoma
Neoadjuvant therapy for locally advanced disease or potentially resectable metastatic melanoma is expected to improve operability and clinical outcomes over upfront surgery and adjuvant treatment as it is for sarcoma, breast, rectal, esophageal, or gastric cancers. Patients with locoregional recurrence after initial surgery and those with advanced regional lymphatic metastases are at a high risk of relapse and melanoma-related death. There is an unmet clinical need to improve the outcomes for such patients. Patients with resectable bulky stage III or resectable stage IV histologically confirmed melanoma were enrolled and received standard-dose BRAFi/MEKi for at least 12 weeks before feasible resection of the pre-therapy target and then received at least for the next 40 weeks further BRAFi/MEKi. Of these patients, 37 were treated with dabrafenib and trametinib, three were treated with vemurafenib and cobimetinib, five with vemurafenib, and one with dabrafenib alone. All patients underwent surgery with 78% microscopically margin-negative resection (R0) resection. Ten patients achieved a complete pathological response. In patients with a major pathological response with no, or less than 10%, viable cells in the tumor, median disease free survival and progression free survival were significantly longer than in patients with a minor pathological response. No patient discontinued neoadjuvant BRAFi/MEKi due to toxicity. BRAFi/MEKi pre-treatment did not result in any new specific complications of surgery. Fourteen patients experienced disease recurrence or progression during post-operative treatment. We confirmed that BRAFi/MEKi combination is an effective and safe regimen in the perioperative treatment of melanoma. Pathological response to neoadjuvant treatment may be considered as a surrogate biomarker of disease recurrence..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cancers - 14(2021), 1, p 110 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Anna M. Czarnecka [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
BRAF |
|---|
| doi: |
10.3390/cancers14010110 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ084856335 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ084856335 | ||
| 003 | DE-627 | ||
| 005 | 20240414221342.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230311s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers14010110 |2 doi | |
| 035 | |a (DE-627)DOAJ084856335 | ||
| 035 | |a (DE-599)DOAJ3ed327f18d424e339b5dbd8111b56f7c | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a Anna M. Czarnecka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF <sup<V600</sup< Mutation-Positive Melanoma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Neoadjuvant therapy for locally advanced disease or potentially resectable metastatic melanoma is expected to improve operability and clinical outcomes over upfront surgery and adjuvant treatment as it is for sarcoma, breast, rectal, esophageal, or gastric cancers. Patients with locoregional recurrence after initial surgery and those with advanced regional lymphatic metastases are at a high risk of relapse and melanoma-related death. There is an unmet clinical need to improve the outcomes for such patients. Patients with resectable bulky stage III or resectable stage IV histologically confirmed melanoma were enrolled and received standard-dose BRAFi/MEKi for at least 12 weeks before feasible resection of the pre-therapy target and then received at least for the next 40 weeks further BRAFi/MEKi. Of these patients, 37 were treated with dabrafenib and trametinib, three were treated with vemurafenib and cobimetinib, five with vemurafenib, and one with dabrafenib alone. All patients underwent surgery with 78% microscopically margin-negative resection (R0) resection. Ten patients achieved a complete pathological response. In patients with a major pathological response with no, or less than 10%, viable cells in the tumor, median disease free survival and progression free survival were significantly longer than in patients with a minor pathological response. No patient discontinued neoadjuvant BRAFi/MEKi due to toxicity. BRAFi/MEKi pre-treatment did not result in any new specific complications of surgery. Fourteen patients experienced disease recurrence or progression during post-operative treatment. We confirmed that BRAFi/MEKi combination is an effective and safe regimen in the perioperative treatment of melanoma. Pathological response to neoadjuvant treatment may be considered as a surrogate biomarker of disease recurrence. | ||
| 650 | 4 | |a melanoma | |
| 650 | 4 | |a neoadjuvant | |
| 650 | 4 | |a BRAF | |
| 650 | 4 | |a targeted therapy | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a Krzysztof Ostaszewski |e verfasserin |4 aut | |
| 700 | 0 | |a Aneta Borkowska |e verfasserin |4 aut | |
| 700 | 0 | |a Anna Szumera-Ciećkiewicz |e verfasserin |4 aut | |
| 700 | 0 | |a Katarzyna Kozak |e verfasserin |4 aut | |
| 700 | 0 | |a Tomasz Świtaj |e verfasserin |4 aut | |
| 700 | 0 | |a Paweł Rogala |e verfasserin |4 aut | |
| 700 | 0 | |a Iwona Kalinowska |e verfasserin |4 aut | |
| 700 | 0 | |a Hanna Koseła-Paterczyk |e verfasserin |4 aut | |
| 700 | 0 | |a Konrad Zaborowski |e verfasserin |4 aut | |
| 700 | 0 | |a Paweł Teterycz |e verfasserin |4 aut | |
| 700 | 0 | |a Andrzej Tysarowski |e verfasserin |4 aut | |
| 700 | 0 | |a Donata Makuła |e verfasserin |4 aut | |
| 700 | 0 | |a Piotr Rutkowski |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Cancers |d MDPI AG, 2010 |g 14(2021), 1, p 110 |w (DE-627)DOAJ000006858 |x 20726694 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g number:1, p 110 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cancers14010110 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/3ed327f18d424e339b5dbd8111b56f7c |z kostenfrei |
| 856 | 4 | 0 | |u https://www.mdpi.com/2072-6694/14/1/110 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2072-6694 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |e 1, p 110 | ||